Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).
1 finding from 1 review
Major bleeding · people with distal DVT
Anticoagulant showed no clear difference in major bleeding ( compared with no intervention or placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with distal DVT
Anticoagulant leads to higher clinically relevant non‐major bleeding ( compared with no intervention or placebo (high certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).
1 finding from 1 review
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in major bleedinge compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral DTIs leads to lower major bleeding (7 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review